A novel explainable AI model accurately detects and localizes breast tumors on MRI, outperforming conventional models—especially in low-cancer-prevalence screening scenarios.
Key Details
- 1The explainable fully convolutional data description (FCDD) model was trained and tested on 9,738 breast MRI exams from 2005-2022, plus an external multicenter dataset.
- 2FCCD outperformed standard binary classification models, achieving AUCs up to 0.84 (balanced tasks) and 0.72 (imbalanced) vs. 0.81 and 0.69 for benchmarks (p<0.001).
- 3In internal and external validation, FCCD consistently showed higher detection performance, e.g., AUC of 0.86 vs. 0.79 (external set).
- 4The model achieved a specificity of 13% vs. 9% for the benchmark at 97% sensitivity in imbalanced (realistic) settings (p=0.02).
- 5It produces interpretable heatmaps to highlight probable tumor areas, addressing the 'black box' issue in AI models.
- 6Researchers note potential to streamline breast MRI screening, including use with abbreviated MRI protocols.
Why It Matters

Source
AuntMinnie
Related News

Survey Reveals Top 6 Concerns About Healthcare AI for 2026
A new survey highlights six main concerns clinicians and patients have about healthcare AI in 2026, including bias, governance, deskilling, hallucinations, accountability, and source validation.

AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.

AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.